News
Bevacizumab, Aflibercept Compared for Neovascular AMD
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
Your search for bevacizumab returned 79 results
News
Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
News
Continued Monitoring Needed for Anti-VEGF Therapy in Macular Edema
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
News
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
ESMO 2021, News
Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
News
Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Drugs in the Pipeline
Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
News
Anti-VEGF Injections May Reduce Glaucoma Burden for Some
Study shows reductions in intraocular pressures and antiglaucoma medication use.
